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Abstract: Attention-deficit/hyperactivity disorder (ADHD) is the most commonly diagnosed 
psychiatric disorder in children and adolescents. Symptoms of ADHD often persist beyond 
childhood and present significant challenges to adults. Pharmacotherapy is a first-line treatment 
option for ADHD across all age groups. The current review’s goals are (a) to critically examine 
the current state of knowledge regarding once-daily formulations of pharmacotherapies for 
treatment of adults with ADHD and (b) to provide clinicians with evidence-based information 
regarding the safety, efficacy and tolerability of once-daily medications for adult ADHD. The 
reviewed body of evidence strongly supports the use of pharmacotherapy as a first-line thera-
peutic option for the treatment of adults with ADHD. The once-daily pharmacological agents 
are effective therapeutic options for the treatment of adults with ADHD. In the US, based on 
the available evidence, once-daily medications are currently underutilized in adults with ADHD 
compared to pediatric population.
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Introduction
Attention-deficit/hyperactivity disorder (ADHD) is one of the most commonly 
diagnosed neurodevelopmental psychiatric disorders in children and adolescents 
characterized by a variety of behavioral and cognitive symptoms, including poor 
impulse control, hyperactivity and inattention. According to the National Health 
and Nutrition Examination Survey on the prevalence, recognition, and treatment of 
ADHD in children age 8–15 in the US, an estimated 2.4 million children, or 8.7% 
of all children in this age group meet the diagnostic criteria for ADHD, based on the 
Diagnostic and Statistical Manual of Mental Disorders –Fourth Edition Text Revision 
(DSM-IV- TR).1,2 Prior to its introduction in the DSM-III in 1980, ADHD and its core 
symptoms, when conceptualized as minimal brain dysfunction, were viewed by many 
clinicians to be specifically related to childhood and adolescence, with a tendency to 
gradually disappear before adulthood.3 However, most of the adult patients, between 
40% and 65%, continue to experience clinically significant symptoms of ADHD 
beyond their youth.4 Today, with an estimated prevalence of this disorder of about 
4.4%, approximately nine million adults in the US may meet the diagnostic criteria 
of ADHD, with only 11% of those adults currently in treatment.4 According to the 
DSM-IV-TR criteria, diagnosis of ADHD requires a presence of six or more symptoms 
of inattention or hyperactivity/impulsivity, in addition to a history of impairment prior 
to seven years of age, with clear evidence of significant impairment in social, school Therapeutics and Clinical Risk Management 2009:5 368
Tcheremissine and Lieving Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
or work functioning, at least in two different settings, and 
symptoms are not better accounted for by another mental 
illness. Three subtypes of ADHD are recognized: ADHD 
predominantly inattentive type (ADHD-I), ADHD predomi-
nantly hyperactive–impulsive type (ADHD-H) and ADHD 
combined type (ADHD-C; both inattentive and hyperactive–
impulsive symptoms), with the ADHD-I subtype being the 
most common diagnosis in adults.1,5
The current diagnostic criteria for ADHD in adults have 
been previously criticized for its lacking of both clinical 
specificity and developmental sensitivity, since the diagnostic 
criteria were developed to be primarily applied in children 
and young adolescents.6 It is also imperative to acknowledge 
that many of the individuals who continue to experience 
symptoms of ADHD during adulthood commonly no longer 
have the same subsets of symptoms that were present during 
childhood and adolescence. Therefore, it has been difficult 
to estimate the rate of persistence of ADHD from childhood 
into adulthood, as prospective studies have produced mixed 
results.7,8
Most of the adults with ADHD tend to report a marked 
decrease in the severity of symptoms of hyperactivity and 
impulsivity, but continue to emphasize the severity of inat-
tention symptoms.9,10 In addition, as environmental demands 
become more complex (eg, needs to balance families and 
careers, issues related to time management, and encoding 
and manipulating information), adults with ADHD report 
more cognitive deficits as well a variety of symptoms such 
as procrastination, low tolerance to frustration, poor motiva-
tion, and insomnia, but these symptoms are not included in 
the DSM-IV-TR criteria. Not surprisingly, significantly fewer 
adults with ADHD attend college, twice as many are divorced 
and half as many are completely satisfied with their profes-
sional lives and career tracks.11 Of those adults with ADHD 
who do attend college, studies suggest that they are at greater 
risk for academic and psychological difficulties.12 In a com-
munity sample, adults with ADHD also were found to have a 
high level of unemployment and educational deficits.11 These 
findings could be explained, at least partially, by differences in 
the baseline of academic achievement and social functioning 
between youth with and without ADHD, since deficits in these 
areas are associated with lower educational achievements, 
which often limit future employment opportunities.13,14 How-
ever, some of these problems also may be related to deficits 
in executive functioning, including sustained attention, work-
ing memory, verbal fluency, as well as motor and mental 
processing speed in adults with ADHD.15–17 These deficits 
are found to be similar to the patterns of neuropsychological 
and executive function deficits observed in children and are 
commonly associated with significant functional impair-
ments.18–20 For instance, the results from a recently conducted 
study looking at the driving performance of individuals with 
ADHD using a simulated driving procedure confirmed that 
adults with ADHD exhibit generally poorer driving perfor-
mance than controls. Although both adults with ADHD and 
controls demonstrated signs of impairment in response to 
alcohol, the findings provide compelling evidence to suggest 
that the cognitive and behavioral deficits associated with 
ADHD might impair driving performance in such a manner 
as to resemble that of an alcohol-intoxicated driver. Moreover, 
alcohol might impair the performance of drivers with ADHD 
in an additive fashion that could considerably compromise 
their driving skill even at blood alcohol concentrations below 
the legal limit.21
Gender differences in adults with ADHD have received 
much less attention. Based on the available data, it appears 
that the male to female ratio in an adult sample is close to 
1.6:1, which is more similar to the gender ratio in epidemio-
logical samples of children and adolescents, which range 
from 1.5:1 to 3:1, but opposite to the gender ratio reported 
in clinical studies with children and adolescents, where the 
male to female ratio is heavily skewed toward boys, ranging 
from 4:1 to 10:1.22,23 At any rate, there is an ample body of 
evidence that ADHD affects a significant number of female 
patients and is as much a source of morbidity and disability 
for females as has been documented for males.24
Across the life span, ADHD has been shown to be 
associated with a high risk for comorbid disorders.25–27 
Based on the National Co-morbidity Survey Replication, 
an epidemiological study of numerous psychiatric disorders, 
lifetime prevalence rates of psychiatric comorbidities of adult 
ADHD were 45% for mood disorders, 59% for anxiety, 36% 
for substance use disorders (SUD), and 70% for impulse 
disorders, including antisocial personality and intermittent 
explosive disorders.26 Data regarding the prevalence of 
comorbid conditions in adults with ADHD are derived from 
two different types of studies. In retrospective studies, the 
comorbid conditions are commonly identified and assessed 
in individuals diagnosed with ADHD in their adulthood, 
while in prospective studies, individuals are diagnosed with 
ADHD in their childhood, and the comorbid conditions 
are assessed and followed during the entire developmental 
course of the disorder.28–30 Interestingly enough, the rates of 
comorbid conditions tend to be lower in prospective stud-
ies than those in retrospective studies. This discrepancy 
could be explained, at least partially, by the impact of the Therapeutics and Clinical Risk Management 2009:5 369
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early therapeutic interventions.31 However, the overall 
relationships between different types of symptoms and 
behaviors within ADHD and its comorbidities are still not 
fully understood. Undoubtedly, the comorbid conditions 
contribute to the delay in diagnosis of ADHD and further 
complicate the clinical course of this disorder. In addition, 
these comorbid conditions may have a pervasive impact on 
the overall therapeutic response to treatment and often may 
require additional therapeutic modalities independent of the 
treatment for ADHD.
Methods
A review of relevant studies was done by searching PubMed 
database from January 1980 to December 2008 using the 
terms: pharmacotherapy of adult ADHD (1027 publica-
tions were identified), once-daily medications for ADHD 
(25 papers were identified), and medications for adult ADHD 
(286 publications were identified), restricting papers to 
English. PubMed is a service of the US National Library of 
Medicine and the National Institute of Health. The individual 
studies were too clinically heterogeneous and methodologi-
cally variable to justify a quantitative meta-analysis. For the 
purpose of this article, the authors chose to examine these 
studies based on the following empirically derived inclusion 
criteria:
•  Study design: randomized controlled trials and quasi-
randomized trials involving alternate allocation or 
assignment by time period.
•  Participants: adults with ADHD.
•  Types of interventions: once-daily pharmacological 
agents.
•  Exclusion criteria: trials that were neither randomized 
nor quasi-randomized.
Selection of the studies for inclusion in this paper 
involved two steps. First, the authors independently reviewed 
the abstracts of all studies identified by the literature search, 
based on inclusion criteria, and excluded those for which 
they agreed that the eligibility criteria were not met. Next, 
the remaining articles were reviewed in detail and the two 
authors made a final decision about inclusion or exclusion 
by consensus.
Once-daily medications  
for the treatment of adult ADHD
The pharmacotherapy remains the primary therapeutic 
modality for ADHD, particularly in the adult population. An 
analysis of data on the total prescriptions for ADHD medica-
tions in the US indicated that almost seven million patients 
filled their prescriptions at least once in 2007. In adults 
alone, an increased prevalence rate of the pharmacological 
treatment of 15.3% has been reported for each year between 
years 2000 and 2005, reaching up to 0.8% of the total adult 
population.32,33
In general, there are two main classes of pharmacological 
agents available to treat ADHD: stimulants (ie, methylphe-
nidate and amphetamine compounds) and nonstimulants (ie, 
atomoxetine).
Stimulants
For nearly fifty years, since methylphenidate (MPH) was 
first introduced to treat hyperactive children with behavioral 
problems, stimulants have remained the mainstay of treat-
ment for ADHD.34 Their therapeutic efficacy is generally 
attributed to the ability of stimulants to block the re-uptake of 
dopamine (DA) and norepinephrine (NE) into the presynaptic 
neuron and increase the release of these monoamines into the 
extra-neuronal space.35 The clinical efficacy and safety of this 
class of drugs in both pediatric and adult populations were 
repeatedly demonstrated in numerous clinical and research 
studies.36,37 At the same time, the therapeutic utility of this 
class of drugs is commonly undermined by a major concern 
that long-term stimulant administration might increase the 
risk for the development of SUD. Consistent with these 
concerns, epidemiological studies have demonstrated that 
between 17%–45% of adults with ADHD have histories of 
alcohol abuse and dependence, and 9%–30% have histories of 
drug abuse or dependence.38 In addition, adults with ADHD 
and comorbid SUD have been reported to have earlier onset 
of substance abuse relative to adults without ADHD.39 There 
is also the issue of potential misuse and diversion of stimu-
lants. Based on data from the 2002 National Survey on Drug 
Use and Health conducted in the US, 2.6% of individuals 
12–17 years of age and 5.9% those of 18–25 years of age 
had misused ADHD stimulants during some period of time.40 
Therefore, when selecting the most optimal therapeutic agent 
for the treatment of ADHD, particularly stimulants, there 
are a number of considerations. For example, most stud-
ies in adults effectively demonstrated that MPH produces 
subjective effects similar to cocaine and dexamphetamine 
in both healthy volunteers and individuals with histories of 
substance abuse.41 In general, the speed of the onset of drug 
effects plays a significant role in determining the reinforc-
ing efficacy of the drug and the overall risk for drug abuse 
or dependency. The central nervous system (CNS)-acting 
pharmacological agents with rapid onset of actions and short 
duration appear to have greater abuse liability than similar Therapeutics and Clinical Risk Management 2009:5 370
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pharmacological agents with longer duration of actions and 
slower onset of action.42,43 This led to the development of a 
number of reformulated, long-acting agents for the treatment 
of ADHD with an increased duration of therapeutic action. 
The rationale behind this strategy is based on the ability of 
new delivery systems to ensure a more gradual onset and 
sustained delivery of medication in the brain, which may 
potentially contribute to decreased drug abuse potential of 
this class of pharmaceuticals.44,45 In the US, there are only 
four extended-release once-daily preparations of stimulants 
approved by the Food and Drug Administration (FDA) for 
the treatment of adults with ADHD.
Methylphenidate
In June 2008, the FDA approved the use of an osmotic 
release oral system formulation of MPH (OROS-MPH) 
in adults with ADHD. The OROS-MPH formulation is an 
extended-release preparation of MPH, designed to increase 
the duration of therapeutic action up to 12 hours as opposed 
to 3–4 hours for the immediate release (IR) formulation of 
MPH with a once-daily administration, which is thought to 
reduce the potential for abuse. The clinical efficacy and safety 
of OROS-MPH were assessed in a randomized, six-week, 
placebo-controlled parallel-design study of OROS MPH in 
141 adult subjects with ADHD.46 OROS-MPH or placebo was 
initiated at 36 mg/day and titrated to optimal dose response, 
depending on efficacy and tolerability, up to 1.3 mg/kg/day. 
The results demonstrated that OROS-MPH is an effective 
option in the treatment of adults with ADHD. Treatment with 
OROS-MPH was associated with clinically and statistically 
significant reductions in DSM-IV symptoms of inattention 
and hyperactivity/impulsivity compared to subjects treated 
with placebo. Forty-four of the subjects (66%) receiving 
OROS-MPH and 23 subjects (39%) (n = 23) receiving 
placebo met a priori definition of response of “much” or 
“very much improved” on the Clinical Global Impression–
Improvement Scale (CGI-I) plus a 30% reduction in Adult 
ADHD Investigator System Report Scale score. In terms of 
side effects, the treatment with OROS-MPH was associated 
with statistically significant increases in systolic and diastolic 
blood pressure, as well as heart rate.
In a double-blind study by Medori and colleagues, 401 
adults 18–63 years of age with ADHD randomized in four 
treatment groups to receive OROS-MPH in three fixed doses 
(18 mg, 36 mg, or 72 mg/day), or placebo daily for five weeks.47 
The primary measure of treatment response was the Conners 
Adult ADHD Rating Scale (CAARS; investigator-rated) at end 
point compared with baseline. Treatment with 18 mg, 36 mg, 
and 72 mg/day OROS-MPH, compared with placebo, was 
associated with significantly larger improvement in CAARS 
total symptom score from baseline to end point than placebo. 
Responders (30% decrease of total score) were 50.5%, 
48.5%, and 59.6% in 18-mg, 36-mg, and 72-mg/day groups, 
respectively, versus 27.4% in placebo. Incidence of adverse 
events was 75%, 76%, and 82% in treatment arms and 66% in 
placebo. The most frequent adverse events included decreased 
appetite (25% OROS-MPH; 7% placebo) and headache (21% 
OROS-MPH; 18% placebo). In OROS-MPH-treated patients, 
4.3% discontinued due to adverse events. In all groups, change 
from baseline in blood pressure occurred at week 1, with only 
slight further increases or decreases from week 1 through 
week 5. In the 18-mg group, one serious adverse event, a 
cerebrovascular accident, possibly related to the study drug, 
was reported in a 59-year-old man who temporarily stopped 
treatment and recovered in 16 days.
For some period of time, heritability of ADHD has been 
an important topic of research endeavors.48 Available data 
from a number of family studies suggest that both parents 
with ADHD are more likely to have their offspring diagnosed 
with ADHD, and children with ADHD are more likely to have 
parents with ADHD.49,50 These observations coupled with the 
results from the studies on cognitive deficits and functional 
impairment in adults with ADHD provided a clinical and 
scientific rationale for examining the effects of pharmacological 
treatment on parental style.51,52 To achieve this objective, the 
effects of OROS-MPH on symptoms and parenting style 
in mothers with ADHD were evaluated in 23 mother-child 
dyads in which both were diagnosed with ADHD based on the 
DSM-IV criteria.53 Mothers underwent a double-blind titration 
of placebo or OROS-MPH (doses: 36, 54, 72, 90 mg/day) for 
a five-week period to an optimal dose (phase 1), followed 
by a two-week random assignment of placebo or maximum 
effective dose (phase 2). The primary outcome measures 
were based on CAARS ratings of maternal ADHD symptoms 
and Alabama Parenting Questionnaire. Secondary outcomes 
included side effects measures. In terms of the core ADHD 
symptoms in mothers during phase 1, the results indicated 
that OROS-MPH produced statistically significant decreases 
in symptoms of inattention in doses of 54, 72, and 90 mg/day 
(p  0.001) and symptoms of hyperactivity/impulsivity in doses 
of 72 (p  0.001) and 90 mg/day (p  0.01). In addition, in 
doses of 72 and 90 mg/day, OROS-MPH produced significant 
reduction in inconsistent discipline (p  0.01) and corporal 
punishment (p  0.001). The dose of 54 mg/day and above of 
OROS-MPH also produced decreases in inconsistent discipline 
and corporal punishment (p  0.05). In Phase 2, estimates Therapeutics and Clinical Risk Management 2009:5 371
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of effect size (Cohen d) were employed due to the limited 
power to detect statistically significant differences. Effect size 
was determined as the difference between the two treatment 
conditions: those randomly assigned to placebo compared to 
those randomly assigned to their most effective dose. Small 
effects on inattention (d = 0.48) and ADHD Index (d = 0.38) 
were found in those who were randomly assigned to medica-
tion versus placebo. In terms of parenting, during Phase 2, 
treatment with OROS-MPH was associated with medium size 
effects on maternal involvement (d = 0.52), poor monitoring/
supervision (d = 0.70), and inconsistent discipline (d = 0.71), 
and much smaller effects on corporal punishment (d = 0.42) 
when compared to placebo. Overall, participants tolerated the 
medication well and reported few side effects during titration, 
such as irritability, stomach aches, headaches, and skin pick-
ing. No symptoms of psychosis, mania, depression or serious 
adverse events were reported. Pairwise comparisons suggested 
significant weight loss from baseline to 54 mg (p  0.05), 72 
mg (p  0.001), and 90 mg (p  0.01), from baseline to 90 mg 
from 0 to 6.9 kg, with a mean ± SD loss of 2.31 ± 1.62 kg.
Dexmethylphenidate
The IR-MPH preparation is a racemic mixture of the d-threo 
and l-threo enantiomers. The ability of MPH to enhance 
neurotransmission of DA and NE is largely attributed to 
d-theo-MPH, which led to the development of dexmethyl-
phenidate (d-MPH).54 Although, in some instances, it was 
assumed that a single enantiomer is identical to half of the 
racemic preparation in terms of its clinical efficacy, which, 
in turn, provides clear advantages of smaller doses and fewer 
side effects, pos hoc studies revealed a possibility of distinctly 
different properties between these two.55 Consequently, the 
clinical efficacy, tolerability and safety of d-MPH underwent 
testing in clinical populations.56 In general, the results were 
similar to those of racemic MPH. However, due to a short 
half-life, frequent administration of d-MPH was needed, 
which provided a rationale for the development of a long-
lasting formulation (extended release or ER). The efficacy and 
safety of d-MPH-ER in adults with ADHD were examined in 
a randomized, double-blind, parallel-group, placebo-controlled 
study conducted by Spencer and colleagues using 20, 30, and 
40 mg daily doses versus placebo.57 The change in scores on 
the ADHD Rating Scale (ADHD-RS) was used as the primary 
efficacy variable. The instrument consists of 18 items adapted 
directly from the DSM-IV ADHD symptom list, modified 
for use in adults. Secondary efficacy outcomes included the 
proportion of patients with improvement 30% in ADHD-RS 
total score and final scores on CGI-I scale. Of the 221 patients 
randomized (127 men; 94 women; mean age 38.7 years), 
184 completed the double-blind phase. For all randomized 
patients, the mean baseline DSM-IV ADHD-RS total score 
(37.0 on a scale of 0 to 54) indicated moderate to marked 
severity of ADHD symptomatology. Their mean baseline 
Global Assessment of Functioning (GAF) score was 54.6. 
The GAF is a numeric scale (0 through 100) used by mental 
health clinicians and physicians to subjectively rate the social, 
occupational and psychological functioning of adults, eg, how 
well or adaptively one is meeting various problems-in-liv-
ing. The score in a range of 51–60 corresponds to moderate 
symptoms of disorder OR any moderate difficulty in social, 
occupational, or school functioning. The results indicated 
that all dosages of d-MPH-ER were significantly superior to 
placebo on both the DSM-IV ADHD-RS inattentive and hyper-
active-impulsive subscales. The highest dose of 40 mg showed 
a trend toward being the most efficacious. All three doses of 
d-MPH-ER produced increases from baseline in GAF scores 
when compared with placebo. Mean changes were 5.4 with 
placebo, 11.1 with d-MPH-ER 20 mg (z = -3.714, p  0.001), 
8.7 with 30 mg (z = -2.864, p = 0.004), and 11.3 with 40 mg 
(z = -2.957, p = 0.003). An improvement of 10 points on the 
GAF scale is considered to be very significant, particularly, 
since the duration of this trial was only five weeks. Importantly, 
the average patient’s score at study end point rose to above 
60, a range that does not generally indicate a need for clinical 
treatment. Overall, the d-MPH-ER was well tolerated in all 
three doses. Most adverse events in the d-MPH-ER group were 
mild (33.3%) or moderate (45.5%) in severity. The severity 
of adverse events was similar across dosage groups. The 
most commonly reported adverse events, including headache 
(23.0% with d-MPH-ER and 11.3% with placebo), decreased 
appetite (18.2% and 11.3%, respectively), dry mouth (15.8% 
and 3.8%, respectively), were consistent with the well-known 
side effects of stimulants. No clinically significant changes in 
ECG or laboratory parameters occurred.
Mixed amphetamine salts
Amphetamines compounds are commonly used as a first-line 
treatment option for ADHD.58 Amphetamine compounds 
are available in IR and extended release (XR) preparations. 
Mixed amphetamine salts XR (MAS XR) capsules contain 
a 1:1 ratio of immediate-to-delayed-release MAS pellets. 
Delayed-release beads are designed to release drug content 
approximately four hours after administration. With the 
delayed-release component, the capsule, taken once/day, 
MAS XR produced similar pharmacokinetic and pharmaco-
dynamic effects to immediate-release MAS taken twice/day. Therapeutics and Clinical Risk Management 2009:5 372
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The safety profile and rapid onset of action of MAS XR are 
similar to those of the IR tablets, but the long-acting formu-
lation provides a persistent 12-hour therapeutic effect with 
once-daily dosing.57 For instance, the pharmacokinetic profile 
of one MAS XR 20-mg capsule is equivalent to that of two 
MAS IR 10-mg tablets dosed 4–6 hours apart.60
The efficacy, safety, and tolerability of MAS XR in adults 
were evaluated during a 4-week randomized, double-blind, 
placebo-controlled study.61 A total of 255 patients with ADHD, 
combined type, were randomized to receive placebo, MAS 
XR 20, 40, or 60 mg daily in a 1:1:1:1 ratio using a block 
randomization schedule. The outcome measures included the 
ADHD-RS (primary) and CAARS-Short Version Self-Report 
(secondary). Results indicated that once-daily MAS XR 20, 40, 
and 60 mg daily doses were safe and effective in the treatment 
of adult ADHD, combined type. Subjects treated with MAS 
XR had significantly improved symptoms compared with 
placebo, as determined by the ADHD-RS. This improvement 
was detected as early as the first week of treatment and was 
maintained throughout the study. The dose-response efficacy 
seemed to be related to symptom severity: adults with mild 
symptoms had significant greater improvements with the 
lowest MAS XR (20 mg/day), whereas those with severe 
symptoms had significantly greater improvements with the 
highest dose (60 mg/day). Importantly, daily symptom relief 
continued for up to 12 hours in all three doses of MAS XR. This 
is an important benefit for individuals with ADHD, given the 
potential for missed doses with multiple daily dose regimens. 
Additionally, compliance with XR stimulant medications is 
improved and the XR platform of these formulations may result 
in a lower abuse liability relative to IR stimulant formulations.62 
The most commonly reported side effects included dry mouth 
(27.4%), decreased appetite (25.5%), insomnia (23.9%), and 
headache (23.6%). Most of the reported side effects were mild 
or moderate in intensity. There are no clinically significant 
cardiovascular effects associated with MAS XR in adults.
Lisdexamfetamine
Lisdexamfetamine (LDX) is the first stimulant prodrug and 
is indicated for the treatment of ADHD. This pharmaco-
logical agent was developed to provide a longer duration 
of the therapeutic effect with less of a propensity to drug 
abuse and drug diversion. After oral ingestion, LDX, a 
therapeutically inactive molecule, is converted to l-lysine, an 
essential aminoacid, and d-amphetamine, a main therapeutic 
component, during first-pass metabolism.63
To evaluate the efficacy and safety, LDX was compared 
to placebo in 3 therapeutic doses, 30, 50, and 70 mg/day, 
in 420 adults aged 18 to 55 years with moderate to severe 
ADHD.64 Following a 7- to 28-day washout, the participants 
were treated with 30, 50, or 70 mg/day LDX or placebo, 
respectively, for four weeks (N = 119, 117, 122, and 62, 
respectively). The 50- and 70-mg/day groups underwent 
forced-dose titration. The primary efficacy measure was the 
clinician-determined ADHD-RS total score. The results indi-
cated that all 3 doses produced larger changes in ADHD-RS 
scores than placebo (placebo = -8.2; 30 mg/day LDX = -16.2; 
50 mg/day LDX = -17.4; 70 mg/day LDX = -18.6; all 
p  0.0001 vs placebo). Importantly, these significant dif-
ferences relative to placebo were observed in each treatment 
group, beginning at week 1 and for each week throughout. 
LDX was generally well-tolerated. Adverse events included 
dry mouth, decreased appetite, and insomnia.
Nonstimulants
The current evidence base strongly supports the use of stimu-
lant medications as first-line agents, even though adults with 
ADHD do not respond to stimulants at the rate of 10%–30%. 
In addition, some of the patients also have a low tolerance to 
the most common side effects of stimulants, such as appetite 
suppression, dry mouth, gastrointestinal discomfort, anxiety/
irritability, sleep difficulties, headache as well as the consider-
able clinical concerns related to impact of this class of medi-
cations on the cardiovascular system. In February 2007, the 
FDA instructed manufacturers of all drug products approved 
for the treatment of ADHD to include warnings about possible 
cardiovascular risks and the possibility of adverse psychiatric 
symptoms. The patient medication guide for MPH preparations 
includes a warning that MPH has been associated with a risk 
of stroke and heart attack in adults. In addition, in individuals 
with ADHD and comorbid bipolar disorder, stimulants have 
demonstrated a worsening of mood instability. The recurrence 
of manic symptoms following the initial stabilization inhibited 
ADHD response to medications.65
These concerns and unmet needs in the pharmacotherapy 
of ADHD in special populations (eg, patients with psychiatric 
comorbidities, patients with histories of SUD) have led to 
the development of the new generation of pharmacologi-
cal agents with different mechanisms of action and lower 
potentials for misuse.
Atomoxetine
Atomoxetine (ATX), the first drug in the emerging class 
of nonstimulants, was approved by the FDA in the US for 
the treatment of ADHD in children, adolescent, and adult 
populations in 2002. A potent and selective inhibitor of the Therapeutics and Clinical Risk Management 2009:5 373
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presynaptic NE transporter, ATX has also demonstrated 
increases of DA in the prefrontal cortex in preclinical studies. 
However, in contrast to stimulants, ATX does not affect the 
nucleus accumbens and striatum, the areas of brain associ-
ated with the reward system. Consequently, ATX has a low 
potential for abuse.66,67
The efficacy and tolerability of ATX in adults with ADHD 
were examined in two clinical trials using randomized, 
double-blind, placebo-controlled designs during a 10-week 
treatment period.68 Five hundred thirty six adults (N = 280 
study I and N = 256 study II) with a diagnosis of ADHD based 
on DSM-IV criteria were randomized to receive ATX or 
placebo. The primary outcome measure for this was the sum 
of the Inattention and Hyperactivity/Impulsivity subscales 
of CAARS rated by the investigator. At each visit, clinicians 
also administered the CGI-Severity Scale, Hamilton Anxiety 
(HAM-A) and Hamilton Depression Scales (HAM-D) to 
assess symptoms of anxiety and depression. In addition, 
the self-rated version of Wender-Reimherr Adult Attention 
Deficit Disorder Scale (WRAADDS) was also completed at 
baseline and end points. ATX was administered in two even 
doses (morning and late afternoon) at a total daily dosage 
of 60 mg. However, for some patients, based on their symp-
tomatology, the daily dosage was increased to 90 mg/day 
after two weeks and 120 mg/day after four weeks. In both 
studies, ATX improved ADHD symptoms as measured 
by the Attention and Hyperactivity/Impulsivity subscales 
compared with placebo groups. These changes were inde-
pendent of the gender and age of participants. Statistically 
significant changes also were observed in both studies in the 
ATX arms on secondary measures, including the CAARS, 
the WRAADS, and the CGI-S. The administration of ATX 
was associated with a number of side effects, including dry 
mouth, increased blood pressure and heart rate, insomnia, 
nausea, decreased appetite, and constipation. Eleven patients 
discontinued their participation due to the side effects in 
study I (six in placebo arm) and 12 patients in study II (three 
in placebo arm). Based on these data, the authors concluded 
that although the tolerability profile in an adult population 
is different compared to children and adolescents, overall 
tolerability was satisfactory, as evident by a discontinuation 
rate less than 10% over the 10-week treatment period.
If the pivotal studies discussed above have unequivocally 
demonstrated the overall safety and efficacy of ATX for 
the treatment of symptoms of ADHD in adult population, 
a number of newly published studies have also supported 
the notion that treatment with ATX has been associated 
with an improvement in quality of life. For example, Adler 
and colleagues examined the quality of life in adults with 
ADHD following their treatment with ATX using a measure 
of health-related quality of life (HRQL; the Medical Out-
comes Study 36-item short-form health survey [SF-36]).69 
A well-recognized and validated instrument, it consists of 
36 questions with a four-week recall covering eight health 
domains (subscales): physical functioning, bodily pain, role 
limitations due to physical problems, emotional problems, 
general health perceptions, mental health, social functioning, 
and vitality. Based on the scores of these subscales, two major 
components were calculated, the Physical Component Sum-
mary (PCS) and the Mental Component Summary (MCS).70 
The primary outcome measure for ADHD symptoms was 
the total symptom score based on the CAARS-Investigator 
Rated. A total of 218 subjects were enrolled into the initial 
period of three to 28 days used to ensure that all subjects met 
the entry criteria. Upon completion of the initial period, the 
participants entered a six-week, double-blind (not placebo-
controlled), acute-treatment period. At the beginning of 
this study period, the patients were randomly assigned in a 
double-blind fashion to one of two treatment dosage groups 
of ATX therapy (40 mg twice a day or 80 mg once a day). 
No other dose changes were permitted during this study. 
If necessary, the participants were allowed to switch between 
the treatment arms, but only once. The decision to switch 
was made between the clinician and the patient. Patients 
unable to tolerate either of these treatment arms or requiring 
a dose reduction due to tolerability were discontinued from 
the study. Study HRQL measures were taken at the baseline 
and at the end of the study period. The CAARS data were 
collected at each post-baseline visit. As expected, the results 
indicated that ATX was clinically effective in reducing 
the overall ADHD symptoms, as measured by the CAARS. 
The results suggested that treatment with ATX also improved 
the subject’s perceived quality of life. This improvement was 
also accompanied by statistically significant improvement 
in HRQL, as measured on the SF-36, in four domains of 
the MCS (ie, vitality, social function, role-emotional, and 
mental health). In addition, for those subjects with the most 
severe ADHD symptoms at baseline, the improvement in the 
MCS measure most strongly correlated with the improve-
ment of ADHD symptoms. Clinical improvement in ADHD 
symptoms did not correlate significantly with changes in four 
domains of the PCS (ie, physical function, role physical, 
bodily pain, and general health).
The considerable disability and the overall negative 
impact of ADHD are not limited to the academic and voca-
tional settings, but also can be evident in social situations and Therapeutics and Clinical Risk Management 2009:5 374
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recreational activities.71 Studies of adults with ADHD have 
found them to be more likely to be involved in automobile acci-
dents due to their poorer driving habits, to have more frequent 
accidents, and to have had more traffic violations, such 
as speeding, compared to control groups.72 In view of this 
problem, Barkley and colleagues examined the effects of 
ATX on driving performance in a small sample of adults.73 
Eighteen participants (8 males and 10 females), between ages 
22 to 60, diagnosed with ADHD combined type (72%) and 
predominantly inattentive type (28%) were included in a final 
sample. To test the original hypothesis, the within-subject 
reversal design was employed. Therefore, all participants were 
exposed to placebo or ATX in a counterbalanced order. Either 
placebo or ATX were titrated upward after one week for three 
additional weeks. The ATX was initiated in a subtherapeutic 
dose of 0.6 mg/kg/daily for a period of one week. Then, 
medication was adjusted upward to 1.2 mg/kg/daily for at 
least a three-week period. The placebo was titrated in the 
same fashion. The outcome measures included ADHD-RS, 
Safe Driving Behavior Rating Scale, Driving Anger Scale, 
and virtual reality driving simulator. The driving simulations 
tests were conducted using a virtual reality 12-minute scenario. 
Participants were exposed to a number of virtual driving 
conditions, such as driving through the highway, country, 
and city while following verbal directions administered by 
the simulator. The driving performance was assessed by an 
independent examiner and the self-rating of simulator driving 
performance. The results indicated that ATX improved the 
self-reported measures of ADHD symptoms, impairments 
ratings, and ratings of driving behavior in natural settings. 
However, no effects of ATX were noted on other measures of 
driving behavior or on the simulator. In addition, the design 
of this study did not allow the investigators to determine 
the potential impact of the practice effects on the simulator 
measures under both placebo and drug conditions.
Antidepressants
Wilens and colleagues evaluated the efficacy and safety of 
an extended-release, once-daily formulation of bupropion 
XL (BUP-XL) in the treatment of adults with ADHD. 
One hundred and sixty-two adults diagnosed with ADHD 
(combined and inattentive types) participated in an eight-
week placebo-controlled, prospective study examining the 
therapeutic efficacy and safety of BUP-XL in doses up to 
450 mg/day. The primary efficacy measure was the propor-
tion of ADHD responders, defined as at least a 30% reduc-
tion in the investigator-rated ADHD-RS, at week 8. The 
results indicated that BUP-XL responders (53%) exceeded 
placebo responders (31%) (p = 0.004 at week 8) with a 
significantly greater proportion of BUP-XL responders at 
week 2 (p = 0.01). Therapeutic benefits of BUP-XL sus-
tained throughout the day compared with placebo (morning 
p = 0.033, afternoon p = 0.004, evening p = 0.024). In addi-
tion, BUP-XL was well-tolerated, as evident by a low rate 
of drug-related study discontinuation (5%), with no serious 
or unexpected adverse events reported.74
Desipramine, a tricycle antidepressant, has been previ-
ously found to be clinically effective in the treatment of 
ADHD in children and adolescents and has been used as an 
alternative therapeutic agent to stimulants for more than two 
decades.75,76 In adults, the clinical efficacy of desipramine was 
examined in a double-blind, six-week, placebo-controlled 
trial.77 Forty-three patients (out of the 168 subjects screened) 
were initially enrolled in this study. The final group of 
patients consisted of 41 patients (20 women and 21 men) 
ranging in age from 21 to 60, with only two patients diag-
nosed with ADHD during childhood. Importantly, most of 
the patients were also diagnosed with at least one comorbid 
psychiatric condition. The average number of comorbid 
conditions was 2.8 per subject. Subsequently, in addition 
to the ADHD-RS, the HAM-D, and HAM-A, and the Beck 
Depression Inventory (BDI) were administered. Desipra-
mine was administered once-daily and initially titrated up 
100 mg/day during week 1, and up to 200 mg/day by week 2. 
At the end of the six-week trial, most of the patients in the 
treatment arm (68%) were considered much to very much 
improved. Therapeutic response was noted at week 2 and 
continued through the duration of the study. Interestingly, 
the therapeutic response to desipramine in this sample was 
independent of gender, socioeconomic status, and lifetime 
history of depression and anxiety disorders.
Emerging once-daily 
pharmacological agents
The increasing awareness of adult ADHD and the unmet 
medical needs for once-daily pharmacological agents have 
led to the development of new long-lasting stimulant medi-
cations. Triple-bead mixed amphetamine salts (SPD465) is 
an oral, once-daily, extended-release preparation developed 
to control symptoms of ADHD for up to 16 hours.78 It con-
tains three types of beads: 33.3% – immediate pulse-release, 
33.3% - delayed pulse-release, and 33.3% – delayed extended-
release beads. This combination provides symptom control not 
only during morning and afternoon activities, but for evening 
activities as well. The efficacy and safety of SPD465 were 
evaluated during a seven-week, randomized, double-blind, Therapeutics and Clinical Risk Management 2009:5 375
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placebo-controlled, parallel-group, dose-optimization study 
of 272 adults with ADHD. The primary outcome measure was 
change in ADHD-RS-IV, which consists of 18 items designed 
to reflect and assess current ADHD symptomatology.79
Secondary outcome measures included CGI, Time-
Sensitive ADHD Symptom Scale (TASS) (measuring 
extended duration), Brown Attention-Deficit Disorder Scale 
(BADDS) (measuring executive function), Adult ADHD 
Impact Module (AIM-A) (measuring quality of life [QOL]), 
and ADHD-RS-IV hyperactivity-impulsivity and inattentive-
ness subscales. The results indicated that SPD465 was effec-
tive in controlling symptoms of adult ADHD up to 16 hours 
when compared to placebo. Importantly, the investigators 
reported significant improvements in executive function and 
QOL. The most common adverse events were typical for 
this class of medications and included insomnia, dry mouth, 
decreased appetite and weight, and headache.
Given that the well-established efficacy of the currently 
available once-daily pharmacological agents for the treatment 
of adult ADHD has been determined through the results 
of clinical trials in which generalizations to typical patient 
populations are difficult, alternative therapeutic options 
and approaches toward the treatment of adult ADHD are 
being investigated. These limitations in treatment options 
are further complicated by the warnings from the FDA that 
stimulants may be associated with sudden death and serious 
cardiovascular events. These concerns, for example, lead to 
the recent suspension of MAS-XR from the market by the 
health authorities in Canada. In 2005, ATX received a “black 
box warning”, a type of warning that indicates that the drug 
carries a significant risk of serious or even life-threatening 
events, from the FDA similar to that of antidepressant 
medications based on reports of increased suicidal thoughts, 
ideations and behavior, though no such warning was required 
based on the results from adult studies.
Guanfacine immediate release (GIR) is a nonstimulant 
adrenergic agonist commonly prescribed to control hyper-
tension and has been also used for a number of years for the 
treatment of ADHD as an off-label alternative to stimulants, 
particularly in children and adolescent populations.80,81 The 
mechanism of action of guanfacine is largely attributed to 
its selective effects on α2a-adrenoreceptors in the prefrontal 
cortex (PFC). Disruption in the PFC and its projections to 
other brain structures can cause distractibility, inattention, 
impairment in memory, and impulsivity, the core symptoms 
of ADHD.82
In an adult population, the clinical utility of GIR for 
the treatment of ADHD was assessed in a double-blind, 
placebo-controlled, crossover study comparing its efficacy 
with that of dextroamphetamine (DAMP).83 Seventeen adults 
diagnosed with ADHD based on the DSM-IV participated 
in three randomized two-week treatment periods of placebo, 
GIR, and DAMP, separated by four-day washout intervals. 
The primary outcome measures were based on the DSM-IV 
ADHD Behavioral Checklist and the Copeland Symptom 
Checklist for Adult ADHD. The results indicated that 
both drugs significantly reduced ADHD symptoms on the 
DSM-IV Adult Behavior Checklist for Adults over placebo 
(p  0.05). The improvement of symptoms did not differ 
significantly between the two drugs. Both medications were 
also well tolerated. No subjects discontinued this trial due 
to side effects. The most commonly reported side effect of 
DAMP was muscle tension (N = 5), and of GIR was fatigue 
(N = 4). At the completion of the study and before unblind-
ing, participants were asked about their drug preference. 
Four subjects chose GIR, 12 chose DAMP, and one chose 
placebo. All subjects choosing DAMP reported that prefer-
ence to DAMP was based on the positive effects of DAMP 
on motivation while GIR did not have this effect. Despite 
the encouraging results, the investigators concluded that the 
overall clinical utility of guanfacine in adults with ADHD 
was limited by the need to administer this medication more 
than once daily.
Guanfacine extended-release formulation (GXR) has 
been specifically developed for the treatment of ADHD, 
and it is designed to allow once-daily dosing and improve 
tolerability. Initially, the single-dose pharmacokinetic 
properties and dose proportionality of GXR following oral 
administration were assessed in 49 healthy adults.84 The 
single-dose pharmacokinetic properties of GXR 1-, 2-, and 
4-mg tablets appeared to be statistically linear. In all three 
doses, GXR appeared to be well tolerated, with no serious 
adverse events, withdrawal, or discontinuation from study 
participation due to adverse events reported.
Although our search failed to identify any double-blind 
placebo-controlled randomized studies of GXR in adults 
with ADHD, the results indicated that safety, efficacy, and 
tolerability of GXR for the treatment of ADHD have been 
recently examined in two large, double-blind pivotal stud-
ies conducted in pediatric population.85,86 In addition, an 
open-label extension study was also conducted to examine 
the long-term (up to two years) safety profile and efficacy of 
GXR children and adolescents.87 Based on the outcomes from 
these studies, the investigators concluded that the adminis-
tration of GXR significantly improved clinical symptoms of 
ADHD compared to placebo and commonly reported adverse Therapeutics and Clinical Risk Management 2009:5 376
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events, such as somnolence, sedation, and fatigue, were mild 
to moderate in severity. GXR 2–4 mg/day was generally safe 
over a long-term (two year) period.
Conclusions
The increasing amount of evidence regarding the impact 
of the persistent symptoms of ADHD from childhood into 
adulthood on critical areas of functioning, including educa-
tion, employment, relationships with family and peers, and 
the development of comorbid conditions such as disorders 
of anxiety, depressive spectrum, and SUD, have led to better 
recognition of ADHD worldwide and even, in some instances, 
to the development of new treatment guidelines.88
In this light, it is imperative to acknowledge that 
childhood-onset and persistent ADHD was found to be asso-
ciated with an early onset of alcohol use disorders, which, 
in turn, was associated with the developmental pathway 
to SUD. Individuals with ADHD were significantly more 
likely than controls to make the transition from an alcohol 
use disorder to a drug use disorder (hazard ratio = 3 .8) and 
were also more likely to continue to abuse psychoactive 
substances following a period of dependence. Consequently, 
a lack of treatment, inadequate treatment, or premature treat-
ment discontinuation during childhood, adolescence, and/or 
early adulthood may increase a risk for the development 
of SUD.89
The long-lasting and once-daily pharmacological agents 
recently introduced into the clinical practice have provided 
clinicians with new options for the treatment of ADHD. On 
a practical level, these newer stimulant and nonstimulant 
medications can enhance compliance and even decrease the 
likelihood of drug misuse, abuse, and diversion. However, 
in comparison to the pediatric population, these pharma-
cological agents are still largely underutilized. According 
to the most recent analysis of US prescribing patterns, the 
long-acting agents account for 78% of ADHD prescriptions 
in the pediatric population (patients prior to 17 years of age), 
but only for 49% of adult ADHD prescriptions, in spite of 
the fact that adults may have even greater difficulties with 
medication compliance and issues related to drug abuse and 
diversion than those of younger age patients.32 A number of 
studies have examined the patterns of compliance in adults 
with ADHD. The results reported by Perwien and colleagues 
suggested that in clinical settings, newly treated adult patients 
continued their treatment for ADHD for several months, but 
they did not consistently adhere to their therapeutic regiment 
for more than two months.90 The poor adherence to the treat-
ment also impacts its effectiveness. In a study conducted by 
Ramos-Quiroga and colleagues, patients were initially treated 
with MPH-IR for three times daily for three months and then 
switched to MPH-OROS once daily.91 The results indicated 
that the percentage of responders went drastically up from 
28.6% from MPH-IR to 91.4% for the OROS formulation. 
The mean numbers of days when no medicine was taken was 
seven-fold higher with IR than with the OROS formulation. 
Almost all of the patients that participated in this trial pre-
ferred the OROS formulation based on the fact that it was 
easier to take, which in turn, resulted in better compliance 
and higher effectiveness of this therapeutic option according 
to the authors.
The neurobiological basis of ADHD is complex. The 
insights from molecular genetics, neuroimaging, neuro-
chemistry, neuropsychology, behavioral pharmacology, 
and epidemiological studies have unequivocally demon-
strated the heterogeneity of ADHD.92,93 For researchers and 
practitioners alike, this heterogeneity makes it difficult to 
decide on the most appropriate therapeutic agent from the 
arsenal of currently available medications, select the most 
efficacious dose, and predict the therapeutic response or side 
effects of their patients. To address some of these concerns, 
future studies are needed involving the adult population of 
patients with ADHD, similar to the recently reported study 
by Newcorn and colleagues.94 In this large double-blind, ran-
domized, placebo-controlled study, the therapeutic response 
to the commonly prescribed OROS-MPH was prospectively 
compared to ATX in children and adolescents with ADHD. 
In addition to the results indicating a differential response 
between the two treatments (OROS-MPH is more effective 
in decreasing symptoms of ADHD than ATX), there was also 
some evidence for preferential response, with one-third of the 
patients responding to either OROS-MPH or ATX, but not 
both. It should also be noted that the results from this study 
add to and extend the currently available body of evidence 
regarding the superiority of stimulants over nonstimulants 
from the earlier reports conducted under less rigorous meth-
odological conditions. The preferential therapeutic response, 
which is likely based on genetic determinates, further under-
lines the importance of the most recent attempts to identify 
the phenotypes and endophenotypes associated with ADHD. 
These efforts are likely to pave the way for more individual-
ized ADHD treatments with a significant therapeutic response 
in a large percentage of patients. It is also plausible that some 
subgroups of patients with ADHD will respond differently 
from the majority. Therefore, additional studies will be 
warranted to examine these differences, including the safety 
and efficacy studies in specific sub-populations of patients Therapeutics and Clinical Risk Management 2009:5 377
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(eg, individuals with co-morbid mood, anxiety, personality, 
eating disorders, and SUD).
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